HONG KONG, May 6, 2025 — Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) will present preliminary study findings on ASC47, a potential weight loss medication that targets adipose tissue and preserves muscle, at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain, through oral and poster presentations.

Oral Presentation Details
Title: ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice
Abstract Category/Topic: Obesity Management and Intervention » Emerging treatments
Abstract Number: 0254
Session: T1 Abstract Session: Novel Drugs. The Seeds for the Future Are Here
Session Date and Time: 11:30-13:00, 13 May 2025 (Malaga Time), 17:30-19:00, 13 May 2025 (Beijing Time)
Presenter: Jinzi Jason Wu

Poster (Guided Poster) Presentation Details
Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study
Abstract Number: 0816
Abstract Category/Topic: Obesity Management and Intervention » Emerging treatments
Session: Track Specific Poster Networking Session
Session Date and Time: 18:00-19:10, 13 May 2025 (Malaga Time), 00:00-01:10, 14 May 2025 (Beijing Time)
Presenter: Jinzi Jason Wu

About ASC47

ASC47, discovered and developed internally at Ascletis, is an adipose-targeted, ultra-long-acting, subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist. ASC47 has distinctive properties that allow it to target adipose tissue, resulting in high, dose-dependent drug concentrations in that tissue. Initial data from Phase Ib single subcutaneous injection studies in Australia involving participants with high LDL-C () have been made public. The U.S. FDA has approved the Investigational New Drug (IND) application for ASC47, when used with semaglutide, for treating obesity.

About European Congress on Obesity

The European Association for the Study of Obesity (EASO), established in 1986, is a federation of professional membership associations from 38 countries in Europe. The ECO is EASO’s annual scientific meeting, gathering experts from all fields related to obesity, including research, prevention, and treatment.

About Ascletis Pharma Inc.

Ascletis, listed on the Hong Kong Stock Exchange (1672.HK), is an innovative, R&D-driven biotech company that manages the complete value chain, encompassing discovery, development, and GMP manufacturing. With a management team possessing extensive experience and a successful history, Ascletis is dedicated to addressing unmet medical needs in metabolic diseases from a global perspective. Ascletis’s metabolic disease pipeline includes several drug candidates in clinical development.

For more information, please visit .

Contact：
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)

SOURCE Ascletis Pharma Inc.